Emtricitabine/Tenofovir Alafenamide
Sponsors
National Institute of Allergy and Infectious Diseases (NIAID), Janssen Pharmaceutica N.V., Belgium, Janssen Research & Development, LLC, Eastern Virginia Medical School
Conditions
Acceptability of Health CareAdherence, MedicationHIV InfectionsHealthy
Phase 1
A Study in Healthy Participants to Assess the Effect of Darunavir, Emtricitabine, and Tenofovir Alafenamide in the Presence of Cobicistat When Administered as a Fixed Dose Combination (Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide) Compared to the Co-administration of the Separate Agents
TerminatedNCT04236453
Start: 2020-01-23End: 2020-04-10Updated: 2020-07-07
A Study in Healthy Participants to Assess the Effect of Darunavir, Emtricitabine, and Tenofovir Alafenamide in the Presence of Cobicistat as Fixed Dose Combination (Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide) Compared With Co-administration of the Separate Agents
CompletedNCT04661397
Start: 2021-01-05End: 2021-07-02Updated: 2025-02-03